Gilead Sciences Quant Upgrade Got Me Thinking

The upgrade got my attention, but positive-looking charts pushed me over the edge.

Jim Cramer: For This Pandemic, and the Next, There Are Several Stocks I Like Now

There's an undercurrent that will grow over time, basically what tailwinds from the pandemic will stay with us after the pandemic's over.

The Doctor Found Something Amiss on the Charts of Teladoc

The name appears bearish and risky right now.

Here's Why I'm Avoiding AstraZeneca Stock

The AZN affair exposes the seedy underbelly of drug manufacturing, and the COVID-19 vaccine is certainly a drug.

Biohaven Pharmaceutical Still Looks Unattractive Based on Its Charts

The migraine drugmaker has been sending weak technical signals for a few months now.

Here's Why I'm Selling Teladoc Health

Volume has picked up dramatically since a selloff in the online health services provider began, and it could get worse.

Let's Try Again on Walgreens Boots Alliance

I hate chasing a stock but it looks like I need to get with the program.

I Like the Growth Prospects for TeleHealth Stock LifeMD

Since we don't have a breakout, I would stay with a half-size approach on any trade here.

Is There Enough Technical Evidence to Go Long Peloton?

Let's see if it's time to jump back on the bike.

Looking at Bristol-Myers Again as the Quants Downgrade It

At current levels BMY is sort-of in no man's land - not bullish and not bearish.